Pharmacokinetic Evaluation of Eltrombopag in ITP Pediatric Patients

Pharmacokinetic Evaluation of Eltrombopag in ITP Pediatric Patients

Background: Eltrombopag (EPAG) is an oral thrombopoietin receptor agonist, approved for refractory primary immune thrombocytopenia (ITP) in pediatric patients. In two pediatric RCTs, EPAG led to an improvement of platelet counts and a reduction in bleeding severity. However, a significant number of...

Full description

Bibliographic Details
Main Authors: Marco Dionisi, Sara Cairoli, Raffaele Simeoli, Francesca De Gennaro, Valeria Paganelli, Roberto Carta, Francesca Rossi, Carlo Dionisi-Vici, Giuseppe Palumbo, Bianca Maria Goffredo
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-12-01
Series:Frontiers in Pharmacology
Subjects:
eltrombopag
primary immune thrombocytopenia (ITP)
pediatric patients
LC-MS/MS
pharmacokinetic (PK) evaluation
area under the concentration–time curve (AUC)
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.772873/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.772873/full

Similar Items